Taiyen Biotech CoTPE:1737 83 EBITDA Margin % is 28.67% as of Dec. 2025, which is 38% above its 10-year median of 20.80. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$32.09 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,947 Consumer Packaged Goods companies, Taiyen Biotech Co ranks better than 87.21% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Taiyen Biotech Co's EBITDA for the
three
months ended in Dec. 2025 was NT$234 Mil. Taiyen Biotech Co's Revenue for the
three
months ended in Dec. 2025 was NT$816 Mil. Therefore, Taiyen Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 28.67%.
Taiyen Biotech Co (TPE:1737) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Taiyen Biotech Co EBITDA Margin % Related Terms
Taiyen Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1737 vs PG, CL, KVUE: EBITDA Margin % Comparison
For the Household & Personal Products subindustry, Taiyen Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co (TPE:1737) has a EBITDA Margin % of 28.67% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Taiyen Biotech Co and its competitors. This is 38% above median its historical median of 20.80. Over the past decade, Taiyen Biotech Co's EBITDA Margin % has ranged from 15.56 to 23.38. According to the industry distribution chart, Taiyen Biotech Co ranks #249 out of 1947 companies in the Consumer Packaged Goods industry, placing it in the top 12.8%.
Is Taiyen Biotech Co's EBITDA Margin % too high?
Taiyen Biotech Co's current EBITDA Margin % of 28.67% is 38% above median its 10-year median of 20.80. Over the past 10 years, this metric has ranged from a low of 15.56 to a high of 23.38. The Consumer Packaged Goods industry median EBITDA Margin % is 8.99. Taiyen Biotech Co's value of 28.67% is 218.9% above this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #249 out of 1947 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's EBITDA Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #249 out of 1947 companies for EBITDA Margin %. This places Taiyen Biotech Co in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.99. Taiyen Biotech Co's value of 28.67% is 218.9% above this benchmark. Historically, Taiyen Biotech Co's own EBITDA Margin % has ranged from 15.56 to 23.38 over the past decade. While the company's 10-year median is 20.80 vs. the industry median of 8.99, Taiyen Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.99, based on 1,947 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current EBITDA Margin % of 28.67% is 218.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Taiyen Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current EBITDA Margin % is 28.67%, which is 38% above median its own 10-year median of 20.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.09, compared to a current price of NT$31.90 — trading 0.6% below its estimated fair value. The current EBITDA Margin % is 28.67%, which is 38% above median its 10-year median of 20.80 and 218.9% above the Consumer Packaged Goods industry median of 8.99. Taiyen Biotech Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current EBITDA Margin % is 28.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$31.90 is trading 0.6% below its estimated GF Value™ of NT$32.09.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
EBITDA Margin %: 28.67% (38% above median its 10-year median of 20.80)
GF Value™: NT$32.09 vs. price of NT$31.90 (0.6% below fair value)
Industry Position: 218.9% above the Consumer Packaged Goods median (#249 of 1947)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score
Get the complete analysis for TPE:1737
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
